Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report

Dupilumab, a monoclonal antibody that targets interleukin-4 and interleukin-13, is one of the approved biologic treatments for moderate-to-severe atopic dermatitis. While it is extremely well tolerated with low rates of adverse events, there have been reports of patients with atopic dermatitis manag...

Full description

Saved in:
Bibliographic Details
Main Authors: Katrina D Cirone, Fiona E Lovegrove
Format: Article
Language:English
Published: SAGE Publishing 2025-02-01
Series:SAGE Open Medical Case Reports
Online Access:https://doi.org/10.1177/2050313X251317811
Tags: Add Tag
No Tags, Be the first to tag this record!